Table 2.
Factors associated with prescription of NOACs vs warfarin for incident OAC users in 2010Q4–2012, 2013–2014, and 2015–2017Q1
| Characteristics | 2010Q4–2012 (n=34 376) | 2013–2014 (n=32 547) | 2015–2017Q1 (n=45 264) |
|---|---|---|---|
| Odds Ratio (95% Confidence Interval) | |||
| Age† | |||
| 18–64 y | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| 65–74 y | 0.59 (0.56–0.63) | 0.56 (0.52–0.59) | 0.54 (0.50–0.57) |
| ≥ 75 y | 0.44 (0.41–0.47) | 0.44 (0.41–0.47) | 0.49 (0.46–0.52) |
| Sex† | |||
| Male | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Female | 1.00 (0.95–1.06) | 1.06 (1.01–1.11) | 1.19 (1.14–1.25) |
| Race/ethnicity† | |||
| Non-Hispanic white | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Non-Hispanic black | 0.86 (0.78–0.95) | 0.96 (0.88–1.04) | 0.95 (0.88–1.03) |
| Hispanic | 0.97 (0.85–1.11) | 0.93 (0.83–1.04) | 1.01 (0.91–1.11) |
| Asian | 1.01 (0.81–1.27) | 1.13 (0.96–1.33) | 1.22 (1.05–1.43) |
| Unknown | 1.01 (0.91–1.13) | 1.01 (0.89–1.15) | 1.08 (0.96–1.21) |
| Education† | |||
| ≤ High school | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Some college | 1.15 (1.08–1.22) | 1.13 (1.07–1.19) | 1.05 (1.00–1.11) |
| ≥ Bachelor degree | 1.66 (1.51–1.82) | 1.43 (1.31–1.57) | 1.43 (1.31–1.56) |
| Unknown | 1.47 (1.22–1.77) | 1.10 (0.86–1.40) | 0.95 (0.80–1.13) |
| Household net worth† | |||
| Low (< $250,000) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Medium ($250,000-$499,999) | 1.18 (1.11–1.26) | 1.09 (1.02–1.15) | 1.05 (0.99–1.11) |
| High (≥ $500,000) | 1.30 (1.20–1.40) | 1.31 (1.22–1.41) | 1.36 (1.27–1.45) |
| Unknown | 0.97 (0.87–1.09) | 1.05 (0.96–1.16) | 1.08 (0.99–1.17) |
| Region of residence† | |||
| Northeast | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Midwest | 0.76 (0.69–0.83) | 0.69 (0.64–0.74) | 0.71 (0.67–0.76) |
| South | 1.32 (1.22–1.44) | 1.40 (1.30–1.50) | 1.58 (1.48–1.69) |
| West | 1.01 (0.92–1.12) | 0.95 (0.86–1.04) | 0.93 (0.85–1.01) |
| Charlson comorbidity index† | |||
| 0–1 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| 2–3 | 0.79 (0.75–0.84) | 0.81 (0.77–0.86) | 0.87 (0.82–0.92) |
| ≥ 4 | 0.56 (0.52–0.60) | 0.58 (0.55–0.62) | 0.65 (0.61–0.69) |
| Prescriber specialty† | |||
| Cardiologist | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Primary care physician | 0.36 (0.34–0.38) | 0.35 (0.33–0.37) | 0.41 (0.39–0.44) |
| Other/unknown | 0.49 (0.46–0.52) | 0.42 (0.39–0.44) | 0.48 (0.46–0.51) |
| Calendar quarter† | 1.17 (1.16–1.18) | 1.15 (1.13–1.16) | 1.12 (1.11–1.13) |
| CHA2DS2-VASc‡ | |||
| 0–1 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| 2–3 | 0.66 (0.61–0.71) | 0.61 (0.55–0.67) | 0.54 (0.49–0.60) |
| ≥ 4 | 0.41 (0.38–0.44) | 0.41 (0.37–0.45) | 0.39 (0.35–0.44) |
| HAS-BLED§ | |||
| 0–1 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| 2 | 0.67 (0.62–0.71) | 0.69 (0.64–0.75) | 0.66 (0.61–0.72) |
| ≥ 3 | 0.55 (0.51–0.58) | 0.54 (0.50–0.58) | 0.55 (0.51–0.59) |
NOAC indicates non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant.
The results came from models that adjusted for all these variables and comorbidity components of CHA2DS2-VASc and HAS-BLED that were not already included in Charlson comorbidity index.
The results came from models that adjusted for race/ethnicity, education, household net worth, region of residence, prescriber specialty, calendar quarter, and comorbidity components of Charlson comorbidity index and HAS-BLED that were not already included in CHA2DS2-VASc.
The results came from models that adjusted for sex, race/ethnicity, education, household net worth, region of residence, prescriber specialty, calendar quarter, and comorbidity components of Charlson comorbidity index and CHA2DS2-VASc that were not already included in HAS-BLED.